Alumis Inc. (NASDAQ:ALMS – Get Free Report) has earned an average recommendation of “Buy” from the nine research firms that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $26.57.
A number of analysts recently commented on the company. Oppenheimer assumed coverage on Alumis in a research report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price target on shares of Alumis in a research report on Monday, March 10th.
Get Our Latest Stock Analysis on ALMS
Institutional Investors Weigh In On Alumis
Alumis Trading Down 0.4 %
Shares of ALMS opened at $4.57 on Friday. The firm has a fifty day simple moving average of $6.07 and a two-hundred day simple moving average of $8.86. Alumis has a 1-year low of $4.36 and a 1-year high of $13.53.
Alumis Company Profile
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
See Also
- Five stocks we like better than Alumis
- Roth IRA Calculator: Calculate Your Potential Returns
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What Makes a Stock a Good Dividend Stock?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What Are Dividend Challengers?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.